**CLAIMS**

1. Use of a mesenchymoangioblast mesenchymal stem cell (MCA-MSC) in the manufacture of a medicament for treating allergic airways disease (AAD)/ asthma in a subject, wherein the MCA-MSC expresses miR-145-5p, miR-181b-5p, and miR-214-3p, but not miR-127-3p and miR-299-5p.

2. The use of claim 1, wherein the MCA-MSC has a $CD73^{+}CD105^{+}CD90^{+}CD146^{+}CD44^{+}CD10^{+}CD31^{-}CD45^{-}$ phenotype.

3. The use of claim 1 or 2, wherein the MCA-MSC is made by a method comprising:

(a) culturing a primitive mesoderm cell in a mesenchymal-colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form; and

(b) culturing the mesenchymal cpolony of (a) adherently to produce the MCA-MSC.

4. The use of any one of claims 1 to 3, wherein the MCA-MSC is to be administered intravenously or intranasally.

5. The use of any one of claims 1 to 4, wherein the MCA-MSC is to be administered intranasally.

6. The use of any one of claims 1 to 5, wherein treating comprises that about $10^{6}$ MCA-MSCs/kg to about $2x10^{8}$ MCA-MSCs/kg, about $10^{6}$ MCA-MSCs/kg, about $5x10^{6}$ MCA-MSCs/kg, or about $10^{7}$ MCA-MSCs/kg are to be administered to the subject.

7. The use of any one of claims 1 to 6, wherein treating comprises that about $1x10^{6}$ to about $1x10^{9}$ MCA-MSCs, about $10^{6}$ to about $2x10^{8}$ MCA-MSCs, about $10^{8}$ MCA-MSCs, about $5x10^{8}$ MCA-MSCs, or about $10^{9}$ MCA-MSCs are to be administered to the subject.

8. The use of any one of claims 1 to 6, wherein the subject is mammalian.

9. The use of any one of claims 1 to 7, wherein the subject is human.

10. The use of any one of claims 1 to 9, wherein the subject has previously been administered a corticosteroid or a β-agonist for treating asthma.

11. The use of any one of claims 1 to 9, wherein the subject has not previously been administered a corticosteroid or a β-agonist for treating asthma.

12. The use of any one of claims 1 to 11, wherein the subject has severe asthma or severe-refractory asthma.

13. The use of any one of claims 1 to 12, wherein treating AAD/ asthma comprises:

(a) decreasing AI, AWR, airway fibrosis, lung fibrosis, goblet cell metaplasia, epithelial thickening, airway transforming growth factor (TGF)-β1 level, subepithelial myofibroblast density, subepithelial collagen concentration, or total lung collagen concentration; or

(b) increasing lung MMP activity; or

(c) any combination of any one or more feature of (a) or any combination of any one or more feature of (a) and (b).

14. The use of any one of claims 1 to 13, wherein the subject is not to be administered a corticosteroid or a β-agonist.

15. The use of any one of claims 1 to 14, wherein the subject is to be administered the MCA-MSCs before, during or after development of AAD/ asthma.